New! View global litigation for patent families

US20020128488A1 - Azomethine compound and oily magenta ink - Google Patents

Azomethine compound and oily magenta ink Download PDF

Info

Publication number
US20020128488A1
US20020128488A1 US10095448 US9544802A US2002128488A1 US 20020128488 A1 US20020128488 A1 US 20020128488A1 US 10095448 US10095448 US 10095448 US 9544802 A US9544802 A US 9544802A US 2002128488 A1 US2002128488 A1 US 2002128488A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
carbon
atoms
group
preferably
ch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10095448
Inventor
Katsuyoshi Yamakawa
Masuji Motoki
Naoki Asanuma
Ryo Suzuki
Tadahisa Sato
Hisashi Mikoshiba
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujifilm Corp
Original Assignee
Fujifilm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; MISCELLANEOUS COMPOSITIONS; MISCELLANEOUS APPLICATIONS OF MATERIALS
    • C09DCOATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D11/00Inks
    • C09D11/30Inkjet printing inks
    • C09D11/32Inkjet printing inks characterised by colouring agents
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; MISCELLANEOUS COMPOSITIONS; MISCELLANEOUS APPLICATIONS OF MATERIALS
    • C09BORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B55/00Azomethine dyes
    • C09B55/009Azomethine dyes, the C-atom of the group -C=N- being part of a ring (Image)
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; MISCELLANEOUS COMPOSITIONS; MISCELLANEOUS APPLICATIONS OF MATERIALS
    • C09DCOATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D11/00Inks
    • C09D11/30Inkjet printing inks
    • C09D11/32Inkjet printing inks characterised by colouring agents
    • C09D11/328Inkjet printing inks characterised by colouring agents characterised by dyes

Abstract

An azomethine compound is represented by the formula (I).
Figure US20020128488A1-20020912-C00001
and R1, L1, L2, R3 and R4 have 20 to 50 carbon atoms in total.

Description

    FIELD OF THE INVENTION
  • [0001]
    The present invention relates to an azomethine compound. In detail, the invention relates to an azomethine compound suitable for a jet printing ink of magenta color.
  • BACKGROUND OF THE INVENTION
  • [0002]
    In an ink-jet recording method, images or characters are printed on image-receiving material with ink ejected from very fine nozzles. The ink-jet recording method can be conducted by using a relatively inexpensive apparatus (i.e., an ink-jet printer), as compared with other printing methods. Further, in proportion to improvement of the method, images of high qualities have been given recently. Now, the ink-jet recording method is one of the most popular image-recording methods.
  • [0003]
    Ink for the ink-jet recording method (i.e., jet printing ink) must not choke the fine nozzles. Since aqueous inks (aqueous solutions of dyes) hardly choke the nozzles, they are widely used. However, the aqueous inks have poor water resistance. Various means (described in Japanese Patent Provisional Publication Nos. 4(1992)-28776, 4(1992)-189876, 4(1992)-261478, 4(1992)-359071 and 4(1992)-359072) have been proposed to improve the water resistance of the aqueous inks or water-soluble dyes. In addition, the water-soluble dyes have poor light resistance.
  • [0004]
    Oil-soluble dyes (described in Japanese Patent Provisional Publication Nos. 1(1989)-170672, 3(1991)-221137, 7(1995)-96163, 8(1996)-218015, 9(1997)-3376, 9(1997)-241565, 9(1997)-286939 and 10(1998)-279873) have been proposed in place of the water-soluble dyes. The oil-soluble dyes are usually incorporated in microcapsules or soaked in polymers when they are used for ink-jet printing. Although the oil-soluble dyes have satisfying water resistance, they are unsatisfactory in color reproduction and color stability.
  • SUMMARY OF THE INVENTION
  • [0005]
    Water-soluble dyes for ink-jet recording have poor resistance against water and light, while oil-soluble dyes are unsatisfactory in color reproduction and color stability.
  • [0006]
    An object of the present invention is to provide an oil-soluble dye excellent in color reproduction and color stability.
  • [0007]
    Another object of the invention is to provide an azomethine compound suitable for a jet printing ink of magenta color.
  • [0008]
    A further object of the invention is to provide an oily magenta ink for ink-jet recording.
  • [0009]
    The applicants have found an azomethine compound having light-absorption characteristics suitable for a magenta dye. The compound is oil-soluble, and is advantageously used in a preparation of an oily magenta ink for ink-jet recording.
  • [0010]
    The present invention provides an azomethine compound represented by the formula (I):
    Figure US20020128488A1-20020912-C00002
  • [0011]
    R1 is an alkyl group having 1 to 16 carbon atoms; R2 is a halogen atom, an alkyl group having 1 to 20 carbon atoms, an alkoxy group having 1 to 20 carbon atoms, an amido group having 2 to 20 carbon atoms, an alkoxycarbonylamino group having 2 to 20 carbon atoms, nitro or cyano; R3 is an alkyl group having 1 to 30 carbon atoms, an aryl group having 6 to 30 carbon atoms, an aryloxyalkyl group having 7 to 30 carbon atoms or an alkoxycarbonylalkyl group having 3 to 30 carbon atoms; R4 is an alkyl group having 1 to 16 carbon atoms; Ll is an alkylene group having 1 to 30 carbon atoms or an arylene group having 6 to 30 carbon atoms; L2 is —CO—NH—, —SO2 —NH—, —O—, —O—CO—or —O—CO—NH—; X is cyano, an alkoxycarbonyl group having 2 to 19 carbon atoms, an alkylsulfonyl group having 1 to 18 carbon atoms, an arylsulfonyl group having 6 to 26 carbon atoms, sulfamoyl, an alkylsulfamoyl group having 1 to 18 carbon atoms or an arylsulfamoyl group having 6 to 26 carbon atoms; Y is hydrogen, a halogen atom, hydroxyl, an alkoxy group having 1 to 20 carbon atoms, an aryloxy group having 6 to 20 carbon atoms or an acyloxy group having 2 to 20 carbon atoms; m is 1, 2, 3 or 4; n is an integer of 1 to 18; p is 0, 1, 2, 3 or 4; and R1, L1, L2, R3 and R4 have 20 to 50 carbon atoms in total.
  • [0012]
    The invention also provides an oily magenta ink in which an azomethine dye represented by the formula (I) is dissolved in an organic solvent.
  • [0013]
    The azomethine compound represented by the formula (I) has excellent characteristics suitable for a magenta dye. Accordingly, the azomethine compound can be advantageously used in a preparation of an oily magenta ink for ink-jet recording.
  • [0014]
    Further, the azomethine compound represented by the formula (I) is excellent in stability to light and heat. Accordingly, the azomethine compound can be used a magenta dye that is excellent in a light resistance and in a heat resistance.
  • DETAILED DESCRIPTION OF THE INVENTION
  • [0015]
    The azomethine compound represented by the formula (I) can be classified into the three embodiments represented by the formulas (Ia), (Ib) and (Ic), respectively. The embodiment of the formula (Ia) is particularly preferred.
    Figure US20020128488A1-20020912-C00003
  • [0016]
    In the formulas (Ia) to (Ic), R1 is an alkyl group having 1 to 16 carbon atoms. The alkyl group preferably has 1 to 12 carbon atoms, more preferably has 1 to 8 carbon atoms, further preferably has 1 to 6 carbon atoms, and most preferably has 1 to 4 carbon atoms. The alkyl group can have a branched chain. Examples of the alkyl groups include methyl and t-butyl.
  • [0017]
    In the formulas (Ia) to (Ic), R2 is a halogen atom, an alkyl group having 1 to 20 carbon atoms, an alkoxy group having 1 to 20 carbon atoms, an amido group having 2 to 20 carbon atoms, an alkoxycarbonylamino group having 2 to 20 carbon atoms, nitro or cyano.
  • [0018]
    The alkyl group preferably has 1 to 12 carbon atoms, more preferably has 1 to 8 carbon atoms, further preferably has 1 to 4 carbon atoms, and most preferably has 1 or 2 carbon atoms. The alkyl group can have a branched chain. Examples of the alkyl groups include methyl and ethyl.
  • [0019]
    The alkoxy group preferably has 1 to 12 carbon atoms, more preferably has 1 to 8 carbon atoms, further preferably has 1 to 4 carbon atoms, and most preferably has 1 or 2 carbon atoms. The alkoxy group can have a branched chain. Examples of the alkoxy groups include methoxy.
  • [0020]
    The amido group preferably has 2 to 12 carbon atoms, more preferably has 2 to 8 carbon atoms, further preferably has 2 to 6 carbon atoms, and most preferably has 3 or 4 carbon atoms. Examples of the amido groups include acetamido.
  • [0021]
    The alkoxycarbonylamino group preferably has 2 to 12 carbon atoms, more preferably has 2 to 8 carbon atoms, further preferably has 2 to 6 carbon atoms, and most preferably has 2 or 3 carbon atoms. Examples of the alkoxycarbonylamino groups include methoxycarbonylamino.
  • [0022]
    In the formulas (Ia) to (Ic) , R3 is an alkyl group having 1 to 30 carbon atoms, an aryl group having 6 to 30 carbon atoms, an aryloxyalkyl group having 7 to 30 carbon atoms or an alkoxylcarbonylalkyl group having 3 to 30 carbon atoms.
  • [0023]
    The alkyl group preferably has 2 to 25, more preferably has 3 to 20 carbon atoms, and most preferably has 4 to 16 carbon atoms. The alkyl group can have a branched chain.
  • [0024]
    Examples of the aryl groups include phenyl and naphthyl. Phenyl is preferred. The aryl group can have a substituent group. Examples of the substituent groups include a halogen atom, an alkyl group having 1 to 24 carbon atoms and an alkoxy group having 1 to 24 carbon atoms. The aryl group has 6 to 30 carbon atoms, preferably 6 to 25 carbon atoms, more preferably 6 to 20 carbon atoms, and most preferably 6 to 16 carbon atoms. The number of the carbon atoms means the number of the total carbon atoms contained in the aryl group and the substituent group.
  • [0025]
    The alkyl moiety of the aryloxyalkyl group can have a branched chain. The aryl moiety of the aryloxyalkyl group is preferably phenyl. The aryloxyalkyl group can have a substituent group. Examples of the substituent groups include a halogen atom, an alkyl group having 1 to 23 carbon atoms and an alkoxy group having 1 to 23 carbon atoms. The aryloxyalkyl group has 7 to 30 carbon atoms, preferably has 7 to 25 carbon atoms, more preferably 7 to 20 carbon atoms, and further preferably 7 to 16 carbon atoms. The number of the carbon atoms means the number of the total carbon atoms contained in the aryloxyalkyl group and the substituent group.
  • [0026]
    The alkoxycarbonylalkyl group preferably has 3 to 25 carbon atoms, more preferably has 4 to 20 carbon atoms, and most preferably has 5 to 16 carbon atoms. Each of the two alkyl moieties of the alkoxycarbonylalkyl group can have a branched chain.
  • [0027]
    In the formula (Ic) , R4 is an alkyl group having 1 to 16 carbon atoms. The alkyl group preferably has 1 to 12 carbon atoms, more preferably has 1 to 8 carbon atoms, further preferably has 1 to 6 carbon atoms, and most preferably has 1 to 4 carbon atoms. The alkyl group can have a branched chain. Examples of the alkyl groups include methyl and ethyl.
  • [0028]
    In the formulas (Ia) to (Ic), L1 is an alkylene group having 1 to 30 carbon atoms or an arylene group having 6 to 30 carbon atoms.
  • [0029]
    The alkylene group preferably has 1 to 25 carbon atoms, more preferably has 2 to 20 carbon atoms, and most preferably has 2 to 16 carbon atoms. The alkylene group can have a branched chain.
  • [0030]
    Examples of the arylene groups include phenylene and naphthylene. Phenylene is preferred. The arylene group can have a substituent group. Examples of the substituent groups include a halogen atom, an alkyl group having 1 to 24 carbon atoms and an alkoxy group having 1 to 24 carbon atoms. The arylene group has 6 to 30 carbon atoms, preferably 6 to 25 carbon atoms, more preferably 6 to 20 carbon atoms, and most preferably 6 to 16 carbon atoms. The number of the carbon atoms means the number of the total carbon atoms contained in the arylene group and the substituent group. In the formulas (Ia) to (Ic), L2 is —CO—NH—, —SO2—NH—, —O—, ——O—CO—or —O—CO—NH—, in each of which the left side is attached to R3, and the right side is attached L1.
  • [0031]
    In the formulas (Ia) to (Ic), X is cyano, an alkoxy-carbonyl group having 2 to 19 carbon atoms, an alkylsulfonyl group having 1 to 18 carbon atoms, an arylsulfonyl group having 6 to 26 carbon atoms, sulfamoyl, an alkylsulfamoyl group having 1 to 18 carbon atoms or an arylsulfamoyl group having 6 to 26 carbon atoms. Cyano and an alkoxycarbonyl group having 2 to 19 carbon atoms are preferred, and cyano is most preferred.
  • [0032]
    The alkoxycarbonyl group preferably has 2 to 8 carbon atoms. Examples of the alkoxycarbonyl groups include methoxycarbonyl and dodecyloxycarbonyl.
  • [0033]
    The alkylsulfonyl group preferably has 1 to 7 carbon atoms. Examples of the alkylsulfonyl groups include methanesulfonyl.
  • [0034]
    The aryl moiety of the arylsulfonyl group is preferably phenyl. The arylsulfonyl group can have a substituent group. Examples of the substituent groups include a halogen atom, an alkyl group having 1 to 20 carbon atoms and an alkoxy group having 1 to 20 carbon atoms. The arylsulfonyl group has 6 to 26 carbon atom, and preferably has 6 to 15 carbon atoms. The number of the carbon atoms means the number of the total carbon atoms contained in the arylsulfonyl group and the substituent group. Examples of the arylsulfonyl groups include benzenesulfonyl.
  • [0035]
    The alkylsulfamoyl group preferably has 1 to 9 carbon atoms. Examples of the alkylsulfamoyl groups include methylsulfamoyl.
  • [0036]
    The aryl moiety of the arylsulfamoyl group is preferably phenyl. The arylsulfamoyl group can have a substituent group. Examples of the substituent groups include a halogen atom, an alkyl group having 1 to 20 carbon atoms and an alkoxy group having 1 to 20 carbon atoms. The arylsulfamoyl group has 6 to 26 carbon atoms, and preferably has 6 to 15 carbon atoms. The number of the carbon atoms means the number of the total carbon atoms contained in the arylsulfamoyl group and the substituent group. Examples of the arylsulfamoyl groups include phenylsulfamoyl.
  • [0037]
    In the formulas (Ia) to (Ic), Y is hydrogen, a halogen atom, hydroxyl, an alkoxy group having 1 to 20 carbon atoms, an aryloxy group having 6 to 20 carbon atoms or an acyloxy group having 2 to 20 carbon atoms. Hydrogen atom is particularly preferred.
  • [0038]
    The alkoxy group preferably has 1 to 12 carbon atoms, more preferably has 1 to 8 carbon atoms, further preferably has 1 to 4 carbon atoms, and most preferably has 1 or 2 carbon atoms. The alkoxy group can have a branched chain. Examples of the alkoxy groups include methoxy and ethoxy.
  • [0039]
    The aryl moiety of the aryloxy group is preferably phenyl. The aryloxy group can have a substituent group. Examples of the substituent groups include a halogen atom, an alkyl group having 1 to 14 carbon atoms and an alkoxy group having 1 to 14carbon atoms. The aryloxy group has 6 to 20 carbon atoms, and preferably has 6 to 15 carbon atoms. The number of the carbon atoms means the number of the total carbon atoms contained in the aryloxy group and the substituent group. Examples of the aryloxy groups include phenoxy.
  • [0040]
    The acyloxy group preferably has 1 to 12 carbon atoms, more preferably has 1 to 8 carbon atoms, further preferably has 1 to 4 carbon atoms, and most preferably has 2 or 3 carbon atoms. Examples of the acyloxy groups include acetoxy.
  • [0041]
    In the formulas (Ia) to (Ic), m is an integer of 1 to 4, preferably is an integer of 1 to 3, and more preferably is 1 or 2. In the case that m is 2, 3 or 4, (CH2)m means an alkylene group of a straight chain.
  • [0042]
    In the formulas (Ia) to (Ic), n is an integer of 1 to 18, preferably is an integer of 1 to 14, more preferably is an integer of 1 or 10, further preferably is an integer of 1 to 8, and most preferably is an integer of 1 to 6. In the case that n is 2 or more, the alkylene group represented by Cn H2n can have a branched chain.
  • [0043]
    In the formulas (Ia) to (Ic), p is 0, 1, 2, 3 or 4, preferably is 0, 1, 2 or 3, more preferably is 0, 1 or 2, further preferably is 0 or 1, and most preferably is 0. In the case that p is 2, 3 or 4, the groups represented by R2 can be different from each other.
  • [0044]
    In the formulas (Ia) and (Ib), R1, L1, L2 and R3 have 20 to 50 carbon atoms in total. In the formula (Ic), R1, L1, L2, R3 and R4 have 20 to 50 carbon atoms in total. The total number of the carbon atoms preferably is 25 to 45.
  • [0045]
    The azomethine compound of the formula (I) preferably has a molecular weight of 600 to 2,000, and more preferably has a molecular weight of 800 to 1,500.
  • [0046]
    Examples of the azomethine compounds represented by the formula (I) are shown below.
    Figure US20020128488A1-20020912-C00004
  • [0047]
    (Ia-1)
  • [0048]
    R1: CH3, R21: H, R22: H,
  • [0049]
    R3: 1-(2,4-di-t-pentylphenoxy)heptyl,
  • [0050]
    L1: —CH2—CH(CH3)—, L2: —CO—NH—, X: cyano,
  • [0051]
    Y: H, m: 2, n: 2,
  • [0052]
    Total number of carbon atoms in R1, L1, L2 and R3: 28
  • [0053]
    (Ia-2)
  • [0054]
    R1: CH3, R21: H, R22: H,
  • [0055]
    R3: 2-octyloxy-5-t-octylphenyl,
  • [0056]
    L1: —CH2—CH(CH3)—, L2: —SO2—NH—, X: cyano,
  • [0057]
    Y: H, m: 2, n: 4,
  • [0058]
    Total number of carbon atoms in R1, L1, L2 and R3: 26
  • [0059]
    (Ia-3)
  • [0060]
    R1: CH3, R21: H, R22: H,
  • [0061]
    R3: 2-octyloxy-5-(2-octyloxy-5-t-octylphenylsulfone-amido)phenyl,
  • [0062]
    L1: —CH2—CH(CH3)—, L2: —SO2—NH—, X: cyano,
  • [0063]
    Y: H, m: 2, n: 1,
  • [0064]
    Total number of carbon atoms in R1, L1, L2 and R3: 40
  • [0065]
    (Ia-4)
  • [0066]
    R1: CH3, R21: H, R22: H,
  • [0067]
    R3: 2-tetradecyloxycarbonylethyl,
  • [0068]
    L1: —CH2—CH(CH3)—, L2: —CO—NH—,
  • [0069]
    X: ethoxycarbonyl, Y: H, m: 2, n: 4,
  • [0070]
    Total number of carbon atoms in R1, L1, L2 and R3: 22
  • [0071]
    (Ia-5)
  • [0072]
    R1: CH3, R21: CH3, R22: H, R3: pentadecyl,
  • [0073]
    L1: -1,4-phenylene-, L2: —CO—NH—, X: cyano,
  • [0074]
    Y: H, m: 2, n: 4,
  • [0075]
    Total number of carbon atoms in R1, L1, L2 and R3: 23
  • [0076]
    (Ia-6)
  • [0077]
    R1: CH3, R21: CH3, R22: H,
  • [0078]
    R3: 1-(2,4-di-t-pentylphenoxy)heptyl,
  • [0079]
    L1: —CH2—CH(CH3)—, L2: —CO—NH—, X: cyano,
  • [0080]
    Y: OH, m: 2, n: 2,
  • [0081]
    Total number of carbon atoms in R1, L1, L2 and R3: 28
  • [0082]
    (Ia-7)
  • [0083]
    R1: CH3, R21: H, R22: H, R3: octadecyl,
  • [0084]
    L1: —CH2—CH2—, L2: —O—, X: methoxycarbonyl,
  • [0085]
    Y: H, m: 1, n: 2,
  • [0086]
    Total number of carbon atoms in R1, L1, L2 and R3: 21
  • [0087]
    (Ia-8)
  • [0088]
    R1: CH3, R21: H, R22: H, R3: hexadecyl,
  • [0089]
    L1: -1,3-phenylene-, L2: —O—CO—, X: cyano,
  • [0090]
    Y: H, m: 3, n: 4,
  • [0091]
    Total number of carbon atoms in R1, Ll, L2 and R3: 24
  • [0092]
    (Ia-9)
  • [0093]
    R1: t—C4H9, R21: H, R22: H,
  • [0094]
    R3:1-(2,4-di-t-pentylphenoxy)pentyl,
  • [0095]
    L1: —CH2—CH(CH3)—, L2: —CO—NH—, X: cyano,
  • [0096]
    Y: H, m: 2, n: 2,
  • [0097]
    Total number of carbon atoms in R1, L1, L2 and R3: 29
  • [0098]
    (Ia-10)
  • [0099]
    R1: t—C4H9, R21: H, R22: H,
  • [0100]
    R3:2-(2-methoxy)ethoxy-5-t-octylphenyl,
  • [0101]
    L1: —CH2—CH(CH3)—, L2: —SO2—NH—, X: cyano,
  • [0102]
    Y: H, m: 2, n: 4,
  • [0103]
    Total number of carbon atoms in R1, L1, L2 and R3: 24
  • [0104]
    (Ia-11)
  • [0105]
    R1: t—C4H9, R21: H, R22: H, R3: tridecyl,
  • [0106]
    L1: -1,3-phenylene-, L2: —CO—NH—, X: cyano,
  • [0107]
    Y: H, m: 2, n: 2,
  • [0108]
    Total number of carbon atoms in R1, L1, L2 and R3: 24
  • [0109]
    (Ia-12)
  • [0110]
    R1: t—C4H9, R21: H, R22: H,
  • [0111]
    R3:2-tetradecyloxycarbonylethyl,
  • [0112]
    L1: -1,4-phenylene-, L2: —CO—NH—, X: cyano,
  • [0113]
    Y: H, m: 2, n: 4,
  • [0114]
    Total number of carbon atoms in R1, L1, L2 and R3: 28
  • [0115]
    (Ia-13)
  • [0116]
    R1: t—C4H9, R21: H, R22: H,
  • [0117]
    R3:1-(2,4-di-t-pentylphenoxy)heptyl,
  • [0118]
    L1: -1,4-phenylene-, L2: —CO—NH—, X: cyano,
  • [0119]
    Y: H, m: 2, n: 2,
  • [0120]
    Total number of carbon atoms in R1, L1, L2 and R3: 34
  • [0121]
    (Ia-14)
  • [0122]
    R1: t—C4H9, R21: H, R22: H,
  • [0123]
    R3:1-(2,4-di-t-pentylphenoxy)heptyl,
  • [0124]
    L1: -1,4-phenylene-, L2: —CO—NH—, X: cyano,
  • [0125]
    Y: H, m: 2, n: 4,
  • [0126]
    Total number of carbon atoms in R1, L1, L2 and R3: 34
  • [0127]
    (Ia-15)
  • [0128]
    R1: t—C4H9, R21: CH3, R22: H,
  • [0129]
    R3:1-(2,4-di-t-pentylphenoxy)heptyl,
  • [0130]
    L1: -1,4-phenylene-, L2: —CO—NH—, X: cyano,
  • [0131]
    Y: OH, m: 2, n: 2,
  • [0132]
    Total number of carbon atoms in R1, L1, L2 and R3: 34
  • [0133]
    (Ia-16)
  • [0134]
    R1: t—C4H9, R21: CH3, R22: H,
  • [0135]
    R3:2-tetradecyloxycarbonylethyl,
  • [0136]
    L1: -1,4-phenylene-, L2: —CO—NH—, X: cyano,
  • [0137]
    Y: H, m: 2, n: 4,
  • [0138]
    Total number of carbon atoms in R1, L1, L2 and R3: 28
  • [0139]
    (Ia-17)
  • [0140]
    R1: t—C4H9, R21: CH3, R22: H, R3: heptadecyl,
  • [0141]
    L1: -1,2-phenylene-, L2: —CO—NH—,
  • [0142]
    X: methoxycarbonyl, Y: H, m: 1, n: 1,
  • [0143]
    Total number of carbon atoms in R1, L1, L2 and R3: 28
  • [0144]
    (Ia-18)
  • [0145]
    R1: t—C4H9, R21: NHCOCH3, R22: H,
  • [0146]
    R3: hexadecyl, L1: -1,3-phenylene-,
  • [0147]
    L2: —SO2—NH—, X: cyano, Y: acetoxy,
  • [0148]
    m: 1, n: 2,
  • [0149]
    Total number of carbon atoms in R1, L1, L2 and R3: 26
  • [0150]
    (Ia-19)
  • [0151]
    R1: t—C4H9, R21 OCH3, R22: H,
  • [0152]
    R3: octadecyl, L1: -1,4-phenylene-,
  • [0153]
    L2: —O—, X: sulfamoyl, Y: phenoxy,
  • [0154]
    m: 3, n: 2,
  • [0155]
    Total number of carbon atoms in R1, L1, L2 and R3: 28
  • [0156]
    (Ia-20)
  • [0157]
    R1: t—C4H9, R21: H, R22: OCH3,
  • [0158]
    R3: hexadecyl, L1: -3-chloro-1,4-phenylene-,
  • [0159]
    L2: —O—, X: methanesulfonyl, Y: methoxy,
  • [0160]
    m: 4, n: 2,
  • [0161]
    Total number of carbon atoms in R1, L1, L2 and R3: 26
  • [0162]
    (Ia-21)
  • [0163]
    R1: C2H5, R21: H, R22: H, R3: pentadecyl,
  • [0164]
    L1: —CH2—CH(CH3)—, L2: —CO—NH—, X: cyano,
  • [0165]
    Y: H, m: 2, n: 2,
  • [0166]
    Total number of carbon atoms in R1, L1, L2 and R3: 21
  • [0167]
    (Ia-22)
  • [0168]
    R1: C3H7, R21: H, R22: H, R3: pentadecyl,
  • [0169]
    L1: —CH2—CH(CH3)—, L2: —CO—NH—, X: cyano,
  • [0170]
    Y: H, m: 2, n: 4,
  • [0171]
    Total number of carbon atoms in R1, L1, L2 and R3: 22
  • [0172]
    (Ia-23)
  • [0173]
    R1: C7H15, R21: CH3, R22: H,
  • [0174]
    R3:2-tetradecyloxycarbonylethyl,
  • [0175]
    L1: -1,4-phenylene-, L2: —CO—NH—, X: cyano,
  • [0176]
    Y: H, m: 2,n: 4,
  • [0177]
    Total number of carbon atoms in R1, L1, L2 and R3: 31
  • [0178]
    (Ia-24)
  • [0179]
    R1: C4H9, R21 H, R22: H,
  • [0180]
    R3:2-tetradecyloxycarbonylethyl,
  • [0181]
    L1: -1,4-phenylene-, L2: —CO—NH—,
  • [0182]
    X: butoxycarbonyl, Y: H, m: 2, n: 2,
  • [0183]
    Total number of carbon atoms in R1, L1, L2 and R3: 28
  • [0184]
    (Ia-25)
  • [0185]
    R1: C3H7, R21: H, R22: H,
  • [0186]
    R3:2-tetradecyloxycarbonylethyl,
  • [0187]
    L1: -1,4-phenylene-, L2: —CO—NH—, X: cyano,
  • [0188]
    Y: OH, m: 3, n: 2,
  • [0189]
    Total number of carbon atoms in R1, L1, L2 and R3: 27
  • [0190]
    (Ia-26)
  • [0191]
    R1: C2H5, R21: H, R22: H,
  • [0192]
    R3:2-tetradecyloxycarbonylethyl,
  • [0193]
    L1: -1,4-phenylene-, L2: —CO—NH—,
  • [0194]
    X: cyano, Y: methoxy, m: 3, n: 2,
  • [0195]
    Total number of carbon atoms in R1, L1, L2 and R3: 26
    Figure US20020128488A1-20020912-C00005
  • [0196]
    (Ib-1)
  • [0197]
    R1: CH3, R2: H,
  • [0198]
    R3:1-(2,4-di-t-butylphenoxy)heptyl,
  • [0199]
    L1: -1,3-phenylene-, L2: —CO—NH—,
  • [0200]
    X: methanesulfonyl, Y: H, m: 2, n: 4,
  • [0201]
    Total number of carbon atoms in R1, L1, L2 and R3: 29
  • [0202]
    (Ib-2)
  • [0203]
    R1: CH3, R2: CH3, R3: tetradecyl,
  • [0204]
    L1: -3-chloro-1,4-phenylene-, L2: —O—,
  • [0205]
    X: cyano, Y: OH, m: 2, n: 2,
  • [0206]
    Total number of carbon atoms in R1, L1, L2 and R3: 21
  • [0207]
    (Ib-3)
  • [0208]
    R1: CH3, R2: NHCO2CH3, R3: hexadecyl,
  • [0209]
    L1: -1,2-phenylene-, L2: —O—,
  • [0210]
    X: sulfamoyl, Y: H, m: 2, n: 1,
  • [0211]
    Total number of carbon atoms in R1, L1, L2 and R3: 23
  • [0212]
    (Ib-4)
  • [0213]
    R1: CH3, R2: CN, R3: pentadecyl,
  • [0214]
    L1: —CH2—CH(CH3)—, L2: —CO—NH—,
  • [0215]
    X: N,N—dimethylsulfamoyl, Y: H,
  • [0216]
    m: 4, n: 1,
  • [0217]
    Total number of carbon atoms in R1, L1, L2 and R3: 20
    Figure US20020128488A1-20020912-C00006
  • [0218]
    (Ic-1)
  • [0219]
    R1: CH3, R3: heptadecyl, R4: CH3,
  • [0220]
    L1: —CH2—CH(CH3)—, L2: —CO—NH—, X: cyano,
  • [0221]
    Y: H, m: 2, n: 4,
  • [0222]
    Total number of carbon atoms in R1, L1, L2, R3 and R4: 23
  • [0223]
    (Ic-2)
  • [0224]
    R1: t—C4H9, R3:2-tetradecyloxycarbonylethyl,
  • [0225]
    R4: C2H5, L1: -1,4-phenylene-,
  • [0226]
    L2: —O—CO—NH—, X: cyano, Y: H,
  • [0227]
    m: 2, n: 4,
  • [0228]
    Total number of carbon atoms in R1, L1, L2, R3 and R4: 30
  • [0229]
    The azomethine compound of the formula (I) can be synthesized by referring to the method described in Japanese Patent Provisional Publication No. 4(1992)-126772. The azomethine compound can be synthesized by a reaction of an azole compound represented by the formula (II) with a p-phenylenediamine compound represented by the formula (III) under an oxidizing condition.
    Figure US20020128488A1-20020912-C00007
  • [0230]
    In the formulas (II) and (III), Z1, Z2, R1, R2, X, Y, m, n and p are the same as those described above for the formula (I); and R is a group eliminable in the reaction. Examples of the eliminable groups (R) include hydrogen, a halogen atom, a heterocyclic group and an aryloxy group.
  • [0231]
    Though a dye of the azomethine compound of the formula (I) has excellent light resistance, an anti-fading agent can further improve its light resistance. The anti-fading agent is described in “Shikizai (written in Japanese)”, 797, 70(1997). Particularly preferred examples of the anti-fading agents are spirochroman and spiroindane.
  • [0232]
    The azomethine compound of the formula (I) is preferably used as a magenta dye, particularly an oily magenta ink suitably used for ink-jet recording.
  • [0233]
    The oily magenta ink for ink-jet recording can be easily prepared according to known publications (for example, Japanese Patent Provisional Publication Nos. 3(1991)-231975, 11(1999)-158422, 11(1999)-172183).
  • [0234]
    Organic solvents employable for preparing the oily magenta ink are hydrocarbons, alcohols, ketones, ethers, esters, nitriles, amides, sulfoxides and sulfones. Esters and ketones are particularly preferred.
  • [0235]
    Examples of the hydrocarbons include petroleum ether, petroleum benzine, tetralin, decalin, 1-amylbenzene and methylnaphthalene.
  • [0236]
    Examples of the alcohols include ethanol, pentanol, heptanol, octanol, cyclohexanol, benzyl alcohol, phenyl-ethyl alcohol, phenylpropyl alcohol, anise alcohol, ethylene glycol monoethyl ether, ethylene glycol monophenyl ether, diethylene glycol monoethyl ether, diethylene glycol monobutyl ether, propylene glycol monoethyl ether, propylene glycol monophenyl ether, dipropylene glycol monomethyl ether, dipropylene glycol monoethyl ether and tripropylene glycol monoethyl ether.
  • [0237]
    Examples of the ketones include methyl ethyl ketone, benzyl methyl ketone, diacetone alcohol and cyclohexanone.
  • [0238]
    Examples of the ethers include butyl phenyl ether, benzyl ethyl ether and hexyl ether.
  • [0239]
    Examples of the esters include ethyl acetate, amyl acetate, benzyl acetate, phenylethyl acetate, phenoxyethyl acetate, ethyl phenylacetate, benzyl propionate, ethyl benzoate, butyl benzoate, ethyl laurate, butyl laurate, isopropyl myristate, isopropyl palmitate, triethyl phosphate, tributyl phosphate, diethyl phthalate, diethyl malonate, dipropyl malonate, diethyl diethylmalonate, diethyl succinate, dibutyl succinate, diethyl glutarate, diethyl adipate, dibutyl adipate, di(2-methoxyethyl) adipate, diethyl sebacate, diethyl maleate, dibutyl maleate, dioctyl maleate, diethyl fumarate, dioctyl fumarate, 3-hexenyl cinnamate, ethylene glycol diacetate, ethylene glycol monoethyl ether acetate and propylene glycol diacetate.
  • [0240]
    Examples of the nitriles include acetonitrile.
  • [0241]
    Examples of the amides include formamide, N,N-di-methylformamide, N,N-dimethylacetamide, N-methyl-2-pyrrolidone, N-vinyl-2-pyrrolidone and N,N-diethyldodecaneamide.
  • [0242]
    Examples of the sulfoxides include dimethyl sulfoxide.
  • [0243]
    Examples of the sulfones include sulfolane.
  • [0244]
    Two or more organic solvents can be used in combination.
  • [0245]
    The oily magenta ink contains the azomethine compound preferably in an amount of 0.2 to 20 wt. %, and more preferably in an amount of 0.5 to 10 wt. %.
  • [0246]
    In addition to the azomethine compound and the organic solvent, the ink can contain additives such as viscosity controlling agent, surface tension controlling agent, specific resistance controlling agent, film-formation controlling agent, UV absorber, antioxidizing agent, anti-fading agent, anti-fungal agent, rust inhibitor, dispersing agent and surface active agent.
  • [0247]
    In ink-jet recording, droplets of the aforementioned oily magenta ink (jet printing ink) are ejected to record an image on recording paper (image-receiving material). In this case, the ink preferably has a viscosity of not more than 40 cp and a surface tension of 20 to 100 dyn/cm.
  • [0248]
    For forming a full-color image, oily inks of cyan and yellow hues can be used together with the oily magenta ink. Further, an oily ink of black hue can be used to control the tone of the image.
  • [0249]
    As the recording paper (image-receiving material) for ink-jet printing, coat paper is preferred from the viewpoints of quality and durability of the image. Recording paper containing polymer mordant is also preferred. The recording paper may contain an inorganic pigment. The recording paper preferably comprises a hydrophilic ink-receiving layer containing a hydrophilic binder. The binder is preferably hardened with a curing agent. Further, the recording paper may contain a matting agent. The layers constituting the recording paper may contain a surface active agent or an organic fluorine compound, and further may contain a polymer latex, anti-fading agent and a fluorescent whitening dye.
  • [0250]
    Ink-jet recording is usually conducted in an on-demand system or in a continuous system. As the head for ink-jet recording (i.e., jet head), some types such as bubble jet type, thermal jet type and ultrasonic type are known.
  • [0251]
    There are also some types of the ink-jet recording method. For example, in one type, many small droplets of thin ink (which is often referred to as “photo-ink”) are jetted out. In another type, two or more inks having the same hue but different concentrations are used to improve image quality. Further, colorless and transparent ink can be also usable.
  • EXAMPLE 1
  • [0252]
    [0252]
    Figure US20020128488A1-20020912-C00008
  • [0253]
    [Synthesis of azomethine compound (Ia-12)]
  • [0254]
    In 1,000 ml of ethyl acetate, 87.9 g of 2-[4-{3-(tetradecyloxycarbonyl) propanoylamino}phenyl]-6-tert-butyl-7-chloropyrazolo[1,5-b][1,2,4]-triazole was dissolved. Independently, 400 ml of methanol and 100 g of sodium carbonate were dissolved in 750 ml of water. The prepared two solutions were mixed, and 39.1 g of 4-amino-N-butyl-N-(2-cyanoethyl) aniline was further added. The obtained solution was dropwise added for 1.5 hour to a solution in which 50.0 g of ammonium persulfate was dissolved in 300 ml of water. The resulting solution was made to react for 1 hour. After 1,000 ml of ethyl acetate and 1,000 ml of water were added, the organic phase was collected. The collected liquid was twice washed with 1,500 ml of water, and the solvent was distilled off. To the obtained oil, 300 ml of acetonitrile was added to precipitate a crystalline product. The product was collected and air-dried, and then recrystallized from 300 ml of methanol. Thus, 45 g of the azomethine compound (Ia-12) was prepared. The yield was 40%, and the melting point was 118-119° C.
  • [0255]
    The starting material in the procedure, namely 2-[4-{3-(tetradecyloxycarbonyl) propanoylamino}phenyl]-6-tert-butyl-7- chloropyrazolo[1,5-b][1,2,4]-triazole, was before-hand synthesized according to the method described in Japanese Patent Publication No. 7(1995)-14941. Further, 4-amino-N-butyl-N-(2-cyanoethyl)-aniline was also beforehand prepared from N-(2-cyanoethyl)-aniline in the known manner (butylation, nitrosoation and reduction reactions).
  • EXAMPLE 2
  • [0256]
    [0256]
    Figure US20020128488A1-20020912-C00009
  • [0257]
    [Synthesis of azomethine compound (Ia-4)]
  • [0258]
    N-butylaniline and ethylacrylate were made to react to prepare N-butyl-N-(2-ethoxycarbonylethyl)aniline, which was then nitrosoated and reduced to synthesize 4-amino-N-butyl-N-(2-ethoxycarbonylethyl)aniline.
  • [0259]
    From the prepared compound, the azomethine compound (Ia-4) was synthesized in the same manner as described in Example 1.
  • EXAMPLE 3
  • [0260]
    [0260]
    Figure US20020128488A1-20020912-C00010
  • [0261]
    [Synthesis of azomethine compounds]
  • [0262]
    The azomethine compounds (Ia-1), (Ia-6), (Ia-13), (Ia-14) and (Ia-15) were synthesized in a similar manner to Example 1 or 2.
  • [0263]
    The melting points of the compounds (Ia-1) and (Ia-6) are lower than room temperature (i.e., they are in the form of oily liquid at room temperature). The melting point of the compound (Ia-13) was 132-133° C. , the melting point of the compound (Ia-14) was 119-120° C. , and the melting point of the compound (Ia-15) was 118-120° C.
  • EXAMPLE 4
  • [0264]
    [Preparation of oily magenta ink]
  • [0265]
    Each of the azomethine compounds (Ia-1), (Ia-6), (Ia-12), (Ia-13), (Ia-14) and (Ia-15) prepared in Examples 1 and 3 was dissolved in ethyl acetate, and thereby it was found that their solubilities are more than 10 wt. %. Thus, oily magenta inks were prepared.
  • [0266]
    Independently, each compound was also dissolved in methyl ethyl ketone, and thereby it was found that their solubilities are also more than 10 wt. %. Thus, other oily magenta inks were prepared.
  • EXAMPLE 5
  • [0267]
    [Measurement of absorption maximum and molar extinction co-efficient]
  • [0268]
    With respect to each of the ethyl acetate-base magenta inks [ethyl acetate solutions of the compounds (Ia-1), (Ia-6), (Ia-12), (Ia-13), (Ia-14) and (Ia-15)] prepared in Example 4, the absorption maximum (λmax) and molar extinction coefficient (ε) were measured. The results are set forth in Table 1.
    TABLE 1
    Azomethine Absorption/maximum Molar extinction
    compound max) coefficient (ε)
    (Ia-1) 512 nm 5.0 × 104
    (Ia-6) 522 nm 5.2 × 104
    (Ia-12) 519 nm 4.8 × 104
    (Ia-13) 517 nm 4.6 × 104
    (Ia-14) 520 nm 4.8 × 104
    (Ia-15) 532 nm 4.9 × 104
  • EXAMPLE 6
  • [0269]
    [Measurement of solubility]
  • [0270]
    With respect to each of the azomethine compounds (Ia-6), (Ia-12) and (Ia-14), 600 mg of the compound was placed in a lidded test tube. After 2 ml of ethyl acetate was added, the mixture was treated with an ultrasonic cleaner for 30 minutes. The resultant liquid was heated and stirred at 65° C. for 1 hour, and then cooled to room temperature. After leaving the test tube in a constant temperature bath at 25° C. for 20 hours, solid particles were filtered off with a micro filter having the pore size of 0.2 μm to prepare an oily magenta ink.
  • [0271]
    Each prepared ink was concentrated to measure the solubility, but solid (crystallite) was not deposited. This indicates that the solubility of each compound is more than 30 wt. %.
  • COMPARISON EXAMPLE 1
  • [0272]
    [Measurement of solubility]
  • [0273]
    With respect to each of the following azomethine compounds (X-1), (X-2), (X-3) and (X-4), 30 mg of the compound was placed in a lidded test tube. After 2 ml of ethyl acetate was added, the mixture was treated with an ultrasonic cleaner for 30 minutes. The resultant liquid was heated and stirred at 65° C. for 1 hour, and then cooled to room temperature. After leaving the test tube in a constant temperature bath at 25° C. for 20 hours, solid particles were filtered off with a micro filter having the pore size of 0.2 μm to prepare an oily magenta ink.
    Figure US20020128488A1-20020912-C00011
  • [0274]
    The azomethine compounds (X-1), (X-2), (X-3) and (X-4) correspond to the compounds 1, 6, 16 and 18 in Japanese Patent Provisional Publication No. 4(1992)-178646 (pages 11-13), respectively.
  • [0275]
    Each prepared ink was concentrated to measure the solubility. The results are set forth in Table 2.
  • COMPARISON EXAMPLE 2
  • [0276]
    [Measurement of absorption maximum]
  • [0277]
    With respect to each of the ethyl acetate-base magenta inks [ethyl acetate solutions of the compounds (X-1), (X-2), (X-3) and (X-4)] prepared in Comparison Example 1, the absorption maximum (λmax) was measured. The results are set forth in Table 2.
    TABLE 2
    Azomethine Absorption maximum
    compound max) Solubility
    (Ia-6) 522 nm 30.2 wt. % or more
    (Ia-12) 519 nm 30.1 wt. % or more
    (Ia-14) 520 nm 30.1 wt. % or more
    (X-1) 504 nm 0.18 wt. %
    (X-2) 520 nm 0.29 wt. %
    (X-3) 511 nm 1.72 wt. %
    (X-4) 536 nm 0.63 wt. %

Claims (14)

  1. 1. An azomethine compound represented by the formula (I):
    Figure US20020128488A1-20020912-C00012
    R1 is an alkyl group having 1 to 16 carbon atoms; R2 is a halogen atom, an alkyl group having 1 to 20 carbon atoms, an alkoxy group having 1 to 20 carbon atoms, an amido group having 2 to 20 carbon atoms, an alkoxycarbonylamino group having 2 to 20 carbon atoms, nitro or cyano; R3 is an alkyl group having 1 to 30 carbon atoms, an aryl group having 6 to 30 carbon atoms, an aryloxyalkyl group having 7 to 30 carbon atoms or an alkoxycarbonylalkyl group having 3 to 30 carbon atoms; R4 is an alkyl group having 1 to 16 carbon atoms; L1 is an alkylene group having 1 to 30 carbon atoms or an arylene group having 6 to 30 carbon atoms; L2 is —CO—NH—, —SO2—NH—, —O—, —O—CO—or —O——CO—NH—; X is cyano, an alkoxycarbonyl group having 2 to 19 carbon atoms, an alkylsulfonyl group having 1 to 18 carbon atoms, an arylsulfonyl group having 6 to 26 carbon atoms, sulfamoyl, an alkylsulfamoyl group having 1 to 18 carbon atoms or an arylsulfamoyl group having 6 to 26 carbon atoms; Y is hydrogen, a halogen atom, hydroxyl, an alkoxy group having 1 to 20 carbon atoms, an aryloxy group having 6 to 20 carbon atoms or an acyloxy group having 2 to 20 carbon atoms; m is 1, 2, 3 or 4; n is an integer of 1 to 18; p is 0, 1, 2, 3 or 4; and R1, L1, L2, R3 and R4 have 20 to 50 carbon atoms in total.
  2. 2. The azomethine compound as defined in claim 1, wherein R1 is an alkyl group having 1 to 12 carbon atoms.
  3. 3. The azomethine compound as defined in claim 1, wherein R2 is a halogen atom, an alkyl group having 1 to 12 carbon atoms, an alkoxy group having 1 to 12 carbon atoms, an amido group having 2 to 12 carbon atoms, an alkoxycarbonylamino group having 2 to 12 carbon atoms, nitro or cyano.
  4. 4. The azomethine compound as defined in claim 1, wherein R3 is an alkyl group having 1 to 25 carbon atoms, an aryl group having 6 to 25 carbon atoms, an aryloxyalkyl group having 7 to 25 carbon atoms or an alkoxycarbonylalkyl group having 3 to 25 carbon atoms.
  5. 5. The azomethine compound as defined in claim 1, wherein R4 is an alkyl group having 1 to 12 carbon atoms.
  6. 6. The azomethine compound as defined in claim 1, wherein L1 is an alkylene group having 1 to 25 carbon atoms or an arylene group having 6 to 25 carbon atoms.
  7. 7. The azomethine compound as defined in claim 1, wherein X is cyano or an alkoxycarbonyl group having 2 to 19 carbon atoms.
  8. 8. The azomethine compound as defined in claim 1, wherein Y is hydrogen.
  9. 9. The azomethine compound as defined in claim 1, wherein m is 1, 2 or 3.
  10. 10. The azomethine compound as defined in claim 1, wherein n is an integer of 1 to 14.
  11. 11. The azomethine compound as defined in claim 1, wherein p is 0, 1, 2 or 3.
  12. 12. The azomethine compound as defined in claim 1, wherein R1, L1, L2, R3 and R4 have 25 to 45 carbon atoms in total.
  13. 13. An azomethine compound represented by the formula (Ia):
    Figure US20020128488A1-20020912-C00013
    wherein R1 is an alkyl group having 1 to 16 carbon atoms; R2 is a halogen atom, an alkyl group having 1 to 20 carbon atoms, an alkoxy group having 1 to 20 carbon atoms, an amido group having 2 to 20 carbon atoms, an alkoxycarbonylamino group having 2 to 20 carbon atoms, nitro or cyano; R3 is an alkyl group having 1 to 30 carbon atoms, an aryl group having 6 to 30 carbon atoms, an aryloxyalkyl group having 7 to 30 carbon atoms or an alkoxycarbonylalkyl group having 3 to 30 carbon atoms; L1 is an alkylene group having 1 to 30 carbon atoms or an arylene group having 6 to 30 carbon atoms; L2 is —CO—NH—, —SO2—NH—, —O—, ——O —CO—or —O—CO—NH—; X is cyano, an alkoxycarbonyl group having 2 to 19 carbon atoms, an alkylsulfonyl group having 1 to 18 carbon atoms, an arylsulfonyl group having 6 to 26 carbon atoms, sulfamoyl, an alkylsulfamoyl group having 1 to 18 carbon atoms or an arylsulfamoyl group having 6 to 26 carbon atoms; Y is hydrogen, a halogen atom, hydroxyl, an alkoxy group having 1 to 20 carbon atoms, an aryloxy group having 6 to 20 carbon atoms or an acyloxy group having 2 to 20 carbon atoms; m is 1, 2, 3 or 4; n is an integer of 1 to 18; p is 0, 1, 2, 3 or 4; and R1, L1, L2, R3 and R4 have 20 to 50 carbon atoms in total.
  14. 14. An oily magenta ink in which an azomethine dye represented by the formula (I) is dissolved in an organic solvent:
    Figure US20020128488A1-20020912-C00014
    R1 is an alkyl group having 1 to 16 carbon atoms; R2 is a halogen atom, an alkyl group having 1 to 20 carbon atoms, an alkoxy group having 1 to 20 carbon atoms, an amido group having 2 to 20 carbon atoms, an alkoxycarbonylamino group having 2 to 20 carbon atoms, nitro or cyano; R3 is an alkyl group having 1 to 30 carbon atoms, an aryl group having 6 to 30 carbon atoms, an aryloxyalkyl group having 7 to 30 carbon atoms or an alkoxycarbonylalkyl group having 3 to 30 carbon atoms; R4 is an alkyl group having 1 to 16 carbon atoms; L1 is an alkylene group having 1 to 30 carbon atoms or an arylene group having 6 to 30 carbon atoms; L2 is —CO—NH—, —SO2—NH—, —O—, —O—CO—or —O—CO—NH—; X is cyano, an alkoxycarbonyl group having 2 to 19 carbon atoms, an alkylsulfonyl group having 1 to 18 carbon atoms, an arylsulfonyl group having 6 to 26 carbon atoms, sulfamoyl, an alkylsulfamoyl group having 1 to 18 carbon atoms or an arylsulfamoyl group having 6 to 26 carbon atoms; Y is hydrogen, a halogen atom, hydroxyl, an alkoxy group having 1 to 20 carbon atoms, an aryloxy group having 6 to 20 carbon atoms or an acyloxy group having 2 to 20 carbon atoms; m is 1, 2, 3 or 4; n is an integer of 1 to 25 18; p is 0, 1, 2, 3 or 4; and R1, L1, L2, R3 and R4 have 20 to 50 carbon atoms in total.
US10095448 1999-03-12 2002-03-13 Azomethine compound and oily magenta ink Abandoned US20020128488A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP6672299 1999-03-12
JP11-066722 1999-03-12
US09515846 US6383276B1 (en) 1999-03-12 2000-02-29 Azomethine compound and oily magenta ink
US10095448 US20020128488A1 (en) 1999-03-12 2002-03-13 Azomethine compound and oily magenta ink

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10095448 US20020128488A1 (en) 1999-03-12 2002-03-13 Azomethine compound and oily magenta ink

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09515846 Division US6383276B1 (en) 1999-03-12 2000-02-29 Azomethine compound and oily magenta ink

Publications (1)

Publication Number Publication Date
US20020128488A1 true true US20020128488A1 (en) 2002-09-12

Family

ID=13324089

Family Applications (2)

Application Number Title Priority Date Filing Date
US09515846 Expired - Fee Related US6383276B1 (en) 1999-03-12 2000-02-29 Azomethine compound and oily magenta ink
US10095448 Abandoned US20020128488A1 (en) 1999-03-12 2002-03-13 Azomethine compound and oily magenta ink

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09515846 Expired - Fee Related US6383276B1 (en) 1999-03-12 2000-02-29 Azomethine compound and oily magenta ink

Country Status (2)

Country Link
US (2) US6383276B1 (en)
EP (1) EP1035172A3 (en)

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040202658A1 (en) * 2003-04-09 2004-10-14 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to TNF-alpha inhibitor
US20050032130A1 (en) * 2003-07-29 2005-02-10 Genentech, Inc. Neutralizing antibody assay and uses therefor
US20050053602A1 (en) * 2003-08-29 2005-03-10 Genentech, Inc. Therapy of ocular disorders
US20050070689A1 (en) * 2001-08-03 2005-03-31 Genentech, Inc. Taci and br3 polypeptides and uses thereof
US20050081746A1 (en) * 2002-01-25 2005-04-21 Deardurff Larrie A. Inkjet dye design
US20050095243A1 (en) * 2003-06-05 2005-05-05 Genentech, Inc. Combination therapy for B cell disorders
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
US20050186206A1 (en) * 2003-12-19 2005-08-25 Genentech, Inc. Detection of CD20 in therapy of autoimmune diseases
US20050191297A1 (en) * 2003-12-19 2005-09-01 Genentech, Inc. Detection of CD20 in transplant rejection
US20050271658A1 (en) * 2004-05-05 2005-12-08 Genentech, Inc. Preventing autoimmune disease
US20060024295A1 (en) * 2004-06-04 2006-02-02 Genentech, Inc. Method for treating lupus
US20060034835A1 (en) * 2002-12-16 2006-02-16 Genentech, Inc. Immunoglobulin variants and uses thereof
US20060051345A1 (en) * 2004-06-04 2006-03-09 Genentech, Inc. Method for treating multiple sclerosis
US20060062787A1 (en) * 2004-07-22 2006-03-23 Genentech, Inc. Method for treating Sjogren's syndrome
US20060073146A1 (en) * 2000-02-16 2006-04-06 Genentech, Inc. Uses of agonists and antagonists to modulate activity of TNF-related molecules
US20060110387A1 (en) * 2004-10-05 2006-05-25 Genentech, Inc. Method for treating vasculitis
US20060188495A1 (en) * 2005-01-13 2006-08-24 Genentech, Inc. Treatment method
US20060233797A1 (en) * 2005-04-15 2006-10-19 Genentech, Inc. Treatment of inflammatory bowel disease (IBD)
US20060246004A1 (en) * 2005-02-07 2006-11-02 Genentech, Inc. Antibody variants and uses thereof
US20060263349A1 (en) * 2005-05-20 2006-11-23 Genentech, Inc. Pretreatment of a biological sample from an autoimmune disease subject
US20060263355A1 (en) * 2005-02-28 2006-11-23 Joanne Quan Treatment of bone disorders
US20070212733A1 (en) * 2005-11-23 2007-09-13 Genentech, Inc. Methods and compositions related to B cell assays
US20080075719A1 (en) * 2004-04-16 2008-03-27 Genentech, Inc. Method for Augmenting B Cell Depletion
US20080171036A1 (en) * 2002-07-25 2008-07-17 Anan Chuntharapai Taci antibodies and uses thereof
US20080279850A1 (en) * 2005-07-25 2008-11-13 Trubion Pharmaceuticals, Inc. B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
US20100003252A1 (en) * 1999-07-12 2010-01-07 Genentech, Inc. Blocking immune response to a graft
US20100135900A1 (en) * 2008-11-13 2010-06-03 Trubion Pharmaceuticals, Inc. Cd37 immunotherapeutic combination therapies and uses thereof
EP2233149A1 (en) 2007-10-16 2010-09-29 ZymoGenetics, Inc. Combination of BLYS inhibition and anti-CD20 agents for treatment of autoimmune disease
US7820161B1 (en) 1999-05-07 2010-10-26 Biogen Idec, Inc. Treatment of autoimmune diseases
WO2011019619A1 (en) 2009-08-11 2011-02-17 Genentech, Inc. Production of proteins in glutamine-free cell culture media
EP2295080A2 (en) 2005-07-25 2011-03-16 Trubion Pharmaceuticals, Inc. B-cell reduction using CD37-specific and CD20-specific binding molecules
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
US20110142836A1 (en) * 2009-01-02 2011-06-16 Olav Mella B-cell depleting agents for the treatment of chronic fatigue syndrome
EP2415483A1 (en) 2005-07-25 2012-02-08 Emergent Product Development Seattle, LLC Single dose use of cd20-specific binding molecules
US8333966B2 (en) 2008-04-11 2012-12-18 Emergent Product Development Seattle, Llc CD37 immunotherapeutics and uses thereof
US8409577B2 (en) 2006-06-12 2013-04-02 Emergent Product Development Seattle, Llc Single chain multivalent binding proteins with effector function
EP2586788A1 (en) 2007-07-09 2013-05-01 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
US8853366B2 (en) 2001-01-17 2014-10-07 Emergent Product Development Seattle, Llc Binding domain-immunoglobulin fusion proteins
US9005612B2 (en) 2001-01-17 2015-04-14 Emergent Product Development Seattle, Llc Binding domain-immunoglobulin fusion proteins
WO2017055542A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
US9683047B2 (en) 2008-09-16 2017-06-20 Genentech, Inc. Methods for treating progressive multiple sclerosis

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001262018A (en) * 2000-03-21 2001-09-26 Fuji Photo Film Co Ltd Ink for ink jet, its production method, and ink jet recording method
JP4082848B2 (en) * 2000-03-21 2008-04-30 富士フイルム株式会社 Coloring composition, ink-jet ink and ink-jet recording method
US6756424B2 (en) * 2000-03-27 2004-06-29 Fuji Photo Film Co., Ltd. Coloring composition, ink-jet ink, and ink jet recording method
JP2001342376A (en) * 2000-03-29 2001-12-14 Fuji Photo Film Co Ltd Coloring composition, ink jet ink and ink jet recording method
JP2001342373A (en) * 2000-03-30 2001-12-14 Fuji Photo Film Co Ltd Coloring composition, ink for ink jet, ink jet recording method and method for protecting ink jet recorded image from fading-out by ozone gas
JP4077600B2 (en) * 2000-05-23 2008-04-16 富士フイルム株式会社 Inkjet ink and ink jet recording method
US6604819B2 (en) 2000-09-28 2003-08-12 Fuji Photo Film Co., Ltd. Ink jet image recording method
JP2002121440A (en) 2000-10-16 2002-04-23 Fuji Photo Film Co Ltd Ink jet image-recording method
US7297454B2 (en) * 2002-07-30 2007-11-20 Hewlett-Packard Development Company, L.P. Colorless inkjet ink compositions for improved image quality

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0764993B2 (en) * 1986-12-09 1995-07-12 富士写真フイルム株式会社 Pyrazoloazole azomethine cyan dye
JPH03231975A (en) * 1990-02-06 1991-10-15 Fuji Photo Film Co Ltd Ink jet recording method
JP2684436B2 (en) * 1990-02-23 1997-12-03 富士写真フイルム株式会社 Thermal transfer dye-providing material
JP2747848B2 (en) * 1990-08-03 1998-05-06 富士写真フイルム株式会社 Thermal transfer dye-providing material
JP2964422B2 (en) * 1990-11-14 1999-10-18 富士写真フイルム株式会社 Pyrazoloazole azomethine dyes
JP2665642B2 (en) * 1992-03-16 1997-10-22 富士写真フイルム株式会社 Pyrazoloazole azomethine dyes and thermal transfer dye providing material containing it
US5476943A (en) * 1993-03-22 1995-12-19 Konica Corporation Dye and heat sensitive transfer material comprising the same
JPH10264517A (en) * 1996-12-09 1998-10-06 Konica Corp Thermal recording material

Cited By (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820161B1 (en) 1999-05-07 2010-10-26 Biogen Idec, Inc. Treatment of autoimmune diseases
US8545843B2 (en) 1999-05-07 2013-10-01 Genentech, Inc. Treatment of vasculitis
US20100003252A1 (en) * 1999-07-12 2010-01-07 Genentech, Inc. Blocking immune response to a graft
US20060073146A1 (en) * 2000-02-16 2006-04-06 Genentech, Inc. Uses of agonists and antagonists to modulate activity of TNF-related molecules
US9005612B2 (en) 2001-01-17 2015-04-14 Emergent Product Development Seattle, Llc Binding domain-immunoglobulin fusion proteins
US8853366B2 (en) 2001-01-17 2014-10-07 Emergent Product Development Seattle, Llc Binding domain-immunoglobulin fusion proteins
US20050070689A1 (en) * 2001-08-03 2005-03-31 Genentech, Inc. Taci and br3 polypeptides and uses thereof
US7407541B2 (en) * 2002-01-25 2008-08-05 Hewlett-Packard Development Company, L.P. Inkjet dye design
US20050081746A1 (en) * 2002-01-25 2005-04-21 Deardurff Larrie A. Inkjet dye design
US8119777B2 (en) 2002-01-25 2012-02-21 Hewlett-Packard Development Company, L.P. Ink jet dye design
US20080078303A1 (en) * 2002-01-25 2008-04-03 Deardurff Larrie A Ink jet dye design
US7449057B2 (en) 2002-01-25 2008-11-11 Hewlett-Packard Development Company, L.P. Ink jet dye design
US20080171036A1 (en) * 2002-07-25 2008-07-17 Anan Chuntharapai Taci antibodies and uses thereof
US8562992B2 (en) 2002-12-16 2013-10-22 Genentech, Inc. Immunoglobulin variants and uses thereof
US20090155257A1 (en) * 2002-12-16 2009-06-18 Genentech, Inc. Immunoglobulin variants and uses thereof
US7799900B2 (en) 2002-12-16 2010-09-21 Genentech, Inc. Immunoglobulin variants and uses thereof
US20060034835A1 (en) * 2002-12-16 2006-02-16 Genentech, Inc. Immunoglobulin variants and uses thereof
WO2004091657A2 (en) 2003-04-09 2004-10-28 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
US7976838B2 (en) 2003-04-09 2011-07-12 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a TNF-α inhibitor
US20060240008A1 (en) * 2003-04-09 2006-10-26 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor
US20040202658A1 (en) * 2003-04-09 2004-10-14 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to TNF-alpha inhibitor
US20080213280A1 (en) * 2003-04-09 2008-09-04 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
US7708994B2 (en) 2003-04-09 2010-05-04 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a TNF-α inhibitor
EP2062916A2 (en) 2003-04-09 2009-05-27 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a TNF-Alpha inhibitor
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
US20100143352A1 (en) * 2003-06-05 2010-06-10 Genentech, Inc. Combination therapy for b cell disorders
US20050095243A1 (en) * 2003-06-05 2005-05-05 Genentech, Inc. Combination therapy for B cell disorders
EP2272868A2 (en) 2003-06-05 2011-01-12 Genentech, Inc. Combination therapy for B cell disorders
US20050032130A1 (en) * 2003-07-29 2005-02-10 Genentech, Inc. Neutralizing antibody assay and uses therefor
US20050053602A1 (en) * 2003-08-29 2005-03-10 Genentech, Inc. Therapy of ocular disorders
US20090136492A1 (en) * 2003-08-29 2009-05-28 Genentech, Inc. Therapy of ocular disorders
US20050186206A1 (en) * 2003-12-19 2005-08-25 Genentech, Inc. Detection of CD20 in therapy of autoimmune diseases
US20050191297A1 (en) * 2003-12-19 2005-09-01 Genentech, Inc. Detection of CD20 in transplant rejection
US20080075719A1 (en) * 2004-04-16 2008-03-27 Genentech, Inc. Method for Augmenting B Cell Depletion
US20050271658A1 (en) * 2004-05-05 2005-12-08 Genentech, Inc. Preventing autoimmune disease
US20060051345A1 (en) * 2004-06-04 2006-03-09 Genentech, Inc. Method for treating multiple sclerosis
EP3130349A1 (en) 2004-06-04 2017-02-15 Genentech, Inc. Method for treating multiple sclerosis
US20100233121A1 (en) * 2004-06-04 2010-09-16 Genentech, Inc. Method for treating multiple sclerosis
US20100303810A1 (en) * 2004-06-04 2010-12-02 Genentech, Inc. Method for treating lupus
US20060024295A1 (en) * 2004-06-04 2006-02-02 Genentech, Inc. Method for treating lupus
US20060062787A1 (en) * 2004-07-22 2006-03-23 Genentech, Inc. Method for treating Sjogren's syndrome
US20060110387A1 (en) * 2004-10-05 2006-05-25 Genentech, Inc. Method for treating vasculitis
US20070025987A1 (en) * 2004-10-05 2007-02-01 Genentech, Inc. Method for Treating Vasculitis
US20060188495A1 (en) * 2005-01-13 2006-08-24 Genentech, Inc. Treatment method
US20080299117A1 (en) * 2005-01-13 2008-12-04 Barron Hal V Treatment Method
US20080095771A1 (en) * 2005-01-13 2008-04-24 Genentech, Inc. Treatment Method
US20060246004A1 (en) * 2005-02-07 2006-11-02 Genentech, Inc. Antibody variants and uses thereof
US20060263355A1 (en) * 2005-02-28 2006-11-23 Joanne Quan Treatment of bone disorders
US20060233797A1 (en) * 2005-04-15 2006-10-19 Genentech, Inc. Treatment of inflammatory bowel disease (IBD)
US20060263349A1 (en) * 2005-05-20 2006-11-23 Genentech, Inc. Pretreatment of a biological sample from an autoimmune disease subject
US20100015055A1 (en) * 2005-05-20 2010-01-21 Genentech, Inc. Pretreatment of a biological sample from an autoimmune disease subject
US7601335B2 (en) 2005-05-20 2009-10-13 Genentech, Inc. Pretreatment of a biological sample from an autoimmune disease subject
EP2295080A2 (en) 2005-07-25 2011-03-16 Trubion Pharmaceuticals, Inc. B-cell reduction using CD37-specific and CD20-specific binding molecules
EP2298815A1 (en) 2005-07-25 2011-03-23 Trubion Pharmaceuticals, Inc. B-cell reduction using CD37-specific and CD20-specific binding molecules
US20080279850A1 (en) * 2005-07-25 2008-11-13 Trubion Pharmaceuticals, Inc. B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
EP2415483A1 (en) 2005-07-25 2012-02-08 Emergent Product Development Seattle, LLC Single dose use of cd20-specific binding molecules
EP2586798A2 (en) 2005-07-25 2013-05-01 Emergent Product Development Seattle, LLC B-cell reduction using CD37-specific and CD20-specific binding molecules
US20070212733A1 (en) * 2005-11-23 2007-09-13 Genentech, Inc. Methods and compositions related to B cell assays
US9726673B2 (en) 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
US8409577B2 (en) 2006-06-12 2013-04-02 Emergent Product Development Seattle, Llc Single chain multivalent binding proteins with effector function
EP2586788A1 (en) 2007-07-09 2013-05-01 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
EP2233149A1 (en) 2007-10-16 2010-09-29 ZymoGenetics, Inc. Combination of BLYS inhibition and anti-CD20 agents for treatment of autoimmune disease
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
US9101609B2 (en) 2008-04-11 2015-08-11 Emergent Product Development Seattle, Llc CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US8333966B2 (en) 2008-04-11 2012-12-18 Emergent Product Development Seattle, Llc CD37 immunotherapeutics and uses thereof
US9683047B2 (en) 2008-09-16 2017-06-20 Genentech, Inc. Methods for treating progressive multiple sclerosis
US20100135900A1 (en) * 2008-11-13 2010-06-03 Trubion Pharmaceuticals, Inc. Cd37 immunotherapeutic combination therapies and uses thereof
US20110142836A1 (en) * 2009-01-02 2011-06-16 Olav Mella B-cell depleting agents for the treatment of chronic fatigue syndrome
WO2011019619A1 (en) 2009-08-11 2011-02-17 Genentech, Inc. Production of proteins in glutamine-free cell culture media
US9714293B2 (en) 2009-08-11 2017-07-25 Genentech, Inc. Production of proteins in glutamine-free cell culture media
US8512983B2 (en) 2009-08-11 2013-08-20 Martin Gawlitzek Production of proteins in glutamine-free cell culture media
WO2017055542A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use

Also Published As

Publication number Publication date Type
EP1035172A2 (en) 2000-09-13 application
US6383276B1 (en) 2002-05-07 grant
EP1035172A3 (en) 2002-11-27 application

Similar Documents

Publication Publication Date Title
US6582502B2 (en) Dye, ink for ink jet recording, and ink jet recording method
US6412936B1 (en) Ink, ink set, ink cartridge, recording unit, image recording process and image recording apparatus
US20020096085A1 (en) Aqueous ink composition
US5482546A (en) Dye, ink containing the same, and ink-jet recording method and instrument using the ink
US6001161A (en) Metal complex for ink jet ink
US7097701B2 (en) Phthalocyanine compound, ink, inkjet recording method, and image forming method
US20040045478A1 (en) Phthalocyanine compound, ink inkjet recording ink, ink-jet recording method and method for improving ozone gas resistance of color image material
US6855195B2 (en) Ink composition and ink jet recording method
US6673140B2 (en) Ink-jet inks and ink sets providing excellent gamut, image quality, and permanence
US5704969A (en) Aqueous ink composition and method of recording using the same
US20040053988A1 (en) Ink set, ink cartridge, inkjet printer and recording method
US20040050291A1 (en) Ink set, ink cartridge, ink jet printer and recording method
US4824485A (en) Recording liquid
US20050081745A1 (en) Ink composition and method of ink-jet recording
US6468338B1 (en) Dye for ink jet ink
US7132012B2 (en) Phthalocyanine compound, ink, ink jet recording method and image forming method
JP2003277662A (en) Ink, inkjet printing method and azo compound
JP2007138124A (en) Ink set, ink cartridge, inkjet printer, inkjet recording method, recorded matter, and color degradation improvement method
JPH09157562A (en) Ink jet recording liquid
JP2002249677A (en) Phthalocyanine compound, coloration composition, ink jet recording ink, and ink jet recording method
US7211134B2 (en) Dye mixture and ink containing the same
US20030061963A1 (en) Ink jet ink set
JPH09241553A (en) Ink jet recording liquid
US20040187738A1 (en) Ink and ink set
JP2001342364A (en) Material and process for heat-sensitive transfer recording, mixture of pigment and metal ion containing compound, color toner, organic electroluminescence element, ink, optical recording medium and color filter